Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 5, 2005 - Issue 4
Submit an article Journal homepage
141
Views
9
CrossRef citations to date
0
Altmetric
Review

Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection

Mini Thomas Massachusetts Institute of Technology, Department of Chemistry and Division of Biological Engineering, Cambridge, MA 02139, USA
,
Qing Ge Massachusetts Institute of Technology, Center for Cancer Research and Department of Biology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. [email protected]
,
James J Lu Massachusetts Institute of Technology, Center for Cancer Research and Department of Biology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. [email protected]
,
Alexander M Klibanov Massachusetts Institute of Technology, Department of Chemical Engineering, Cambridge, MA 02139, USA
&
Jianzhu Chen Massachusetts Institute of Technology, Center for Cancer Research and Department of Biology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. [email protected]
Pages 495-505 | Published online: 22 Apr 2005

Bibliography

  • CHUAH MK, COLLEN D VANDENDRIESSCHE T: Gene therapy for hemophilia. J. Gene Med. (2001) 3(1):3–20.
  • MONTIER T, DELEPINE P, PICHON C, FEREC C, PORTEOUS DJ, MIDOUX P: Non-viral vectors in cystic fibrosis gene therapy: progress and challenges. Trends Biotech. (2004) 22(11):586–592.
  • IZQUIERDO M: Short interfering RNAs as a tool for cancer gene therapy Cancer Gene Ther. (2004) 12(3):217–227.
  • ANDERSON DG, PENG W, AKINC A et al.: A polymer library approach to suicide gene therapy for cancer Proc. Nail. Acad. Sci. USA (2004) 101(45):16028–16033.
  • QUARCK R, HOLVOET P: Gene therapy approaches for cardiovascular diseases. Curr. Gene Ther. (2004) 4(2):207–223.
  • LOWENSTEIN PR, CASTRO MG: Recent advances in the pharmacology of neurological gene therapy. Curr. Opin. Pharmacol (2004) 4(1):91–97.
  • FANNING G, AIVIADO R, SYMONDS G: Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen./ Gene Med. (2003) 5(8):645–653.
  • PENG Z, XIAO Z, WANG Yet al.: Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther. (2004) 11(11):707–712.
  • KURRECK J: Antisense technologies. Improvement through novel chemical modifications. Eur. j Biochem. (2003) 270(8):1628–1644. A good review on antisense strategies.
  • SCANLON KJ: Anti-genes: siRNA, ribozymes and antisense Curr. Pharm. Biotechnol. (2004) 5(5):415–420.
  • FIRE A:. XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669):806–811.
  • •The first paper to describe RNAi.
  • ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494–498.
  • ••The first paper to describe siRNA-mediatedgene silencing in mammalian cells.
  • MCMANUS MT, SHARP Pk Gene silencing in mammals by small interfering RNAs. Nat. Rev. Gen. (2002) 3(10:737–747.
  • THOMAS M, KLIBANOV AM: Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol (2003) 62(1):27–34.
  • REID AH, FANNING TG, JANCZEWSKI TA, TAUBENBERGER JK: Characterization of the 1918 'Spanish' influenza virus neuraminidase gene. Proc. Natl. Acad. Sci. USA (2000) 97(12):6785–6790.
  • WOOD JM, ROBERTSON JS: From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol (2004) 2(10):842–847.
  • GOVAERT TM, THUS CT, MASUREL N, SPRENGER MJ, DINANT GJ, KNOTTNERUS JA: The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA (1994) 272(21):1661–1665.
  • MAEDA T, SHINTANI Y, NAKANO K, TERASHIMA K, YAMADA Y: Failure of inactivated influenza A vaccine to protect healthy children aged 6-24 months. Pediatr. Int. (2004) 46(2):122–125.
  • RUBEN FL: Inactivated influenza virus vaccines in children. Clin. Infra. Dis. (2004) 38(5):678–688.
  • MONTO AS: The role of antivirals in the control of influenza. Vaccine (2003) 21(16):1796–1800.
  • KISO M, MITAMURA K, SAKAI-TAGAWA Yet al: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet (2004) 364(9430:759–765.
  • GE Q, MCMANUS MT, NGUYEN T et al.: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl Acad. Sci. USA (2003) 100(5):2718–2723.
  • GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Nail Acad. Sci. USA (2004) 101(23):8676–8681.
  • ••The first report on the in vivo inhibition ofinfluenza infection by polycation-mediated siRNA delivery.
  • KAISER J: Influenza: girding for disaster. Searching for all-powerful flu weapons. Science (2004) 306(5695):395.
  • NAYAK DP, HUT EK, BARMAN S: Assembly and budding of influenza virus. Virus Res. (2004) 106(2):147–165.
  • HAY, STEVENS DJ, SKEHEL JJ, WILEY DC: H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J. (2002) 21(5):865–875.
  • WEBBY RJ, ROSSOW K, ERICKSON G, SIMS Y, WEBSTER R: Multiple lineages of antigenically and genetically diverse influenza A virus co-circulate in the United States swine population. Virus Res. (2004) 103(1-2):67–73.
  • KOBASA D, TAKADA A, SHINYA K et al.: Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature (2004) 431(7009):703–707.
  • SUZUKI H, SAITO R, MASUDA H, OSHITANI H, SATO M, SATO I: Emergence of amantadine-resistant influenza A viruses: epidemiological study. J. Infect. Chemother. (2003) 9(3):195–200.
  • SAITO R, SAKAI T, SATO I et ill.: Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J. Clin. Microbiol (2003) 41(5):2164–2165.
  • GUBAREVA LV, KAISER L, HAYDEN FG: Influenza virus neuraminidase inhibitors. Lancet (2000) 355(9206):827–835.
  • STEINDL T, LANGER T: Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. J. Chem. Inf Comput. Sci. (2004) 44(5):1849–1856.
  • BELSHE RB, NICHOL KL, BLACK SB et al.: Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin. Infect. Dis. (2004) 39(7):920–927.
  • DYER O: Shortage of flu vaccine in US sparks political row. Br. Med. J. (2004) 329(7473):998.
  • MAMMEN M, CHOI SK, WHITESIDES JM: Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. (1998) 37(20):2754–2794.
  • REUTER JD, MYC A, HAYES MM et al: Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers. Bioconjug. Chem. (1999) 10(2):271–278.
  • SPEVAK W, NAGY JO, CHARYCH DH, SCHAEFER ME, GIIBERT JH, BEDNARSKI MD: Polymerized liposomes containing C-glycosides of sialic acid: potent inhibitors influenza virus in vitro infectivity. J. Am. Chem. Soc. (1993) 115(3):1146–1147.
  • TOTANI K, KUBOTA T, KURODA T et al.: Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. Glycobiology (2003) 13(5):315–326.
  • LANDERS JJ, CAO Z, LEE I et al: Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. J. Infect. Dis. (2002) 186(9):1222–1230.
  • GAMBARYAN AS, TUZIKOV AB, CHINAREV AA, JUNEJA LR, BOVIN NV, MATROSOVICH MN: Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection. Antiviral Res. (2002) 55(1) :201–205.
  • GITLIN L, KARELSKY S, ANDINO R: Short interfering RNA confers intracellular antiviral immunity in human cells. Nature (2002) 418(6896):430–434.
  • NOVINA CD, MURRAY MF, DYKXHOORN DM et al.: siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8(7):681–686.
  • HAN W, WIND-ROTOLO M, KIRKMAN RL, MORROW CD: Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. Virology (2004) 330(1):221–232.
  • YOKOTA T, SAKAMOTO N, ENOMOTO N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. (2003) 4(6):602–608.
  • LU A, ZHANG H, ZHANG X et ill.: Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology (2004) 324(1):84–89.
  • ZHENG BJ, GUAN Y, TANG Q et al: Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir. Ther. (2004) 9(3):365–374.
  • GILADI H, KETZINEL-GILAD M, RIVKIN L, FELIG Y, NUSSBAUM O, GALUN E: Small interfering RNA inhibits hepatitis B virus replication in mice. MoL Ther. (2003) 8(5):769–776.
  • MCCAFFREY AP, NAKAI H, PANDEY K et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol (2003) 21(6):639–644.
  • CHEN W, YAN W, DU Q et ill.: RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. J. Virol (2004) 78(13):6900–6907.
  • ROSENECKER J, NAUNDORF S, GERSTING SW et al.: Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J. Gene Med. (2003) 5(1):49–60.
  • ERNST N, ULRICHSKOTTER S, SCHMALIX WA et al.: Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant. J. Gene Med. (1999) 1(5):331–340.
  • RUDOLPH C, LAUSIER J, NAUNDORF S, MULLER RH, ROSENECKER J: In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med. (2000) 2(4):269–278.
  • KABANOV AV: Taking polycation gene delivery systems from in vitro to in vivo. Pharm. Sci. Technol. Today (1999) 2(9):365–372.
  • MARSHALL E: Gene therapy death prompts review of adenovirus vector. Science (1999) 286(5448):2244–2245.
  • HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415–419.
  • BOYCE N: Trial halted after gene shows up in semen. Nature (2001) 414(6865):677.
  • BELTING M: Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. (2003) 28(3):145–151.
  • ZUHORN IS, OBERLE V, VISSER WH et al.: Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex shape, DNA translocation, and transfection efficiency. Biophys. J. (2002) 83(4):2096–2108.
  • BOUSSIF O, LEZOUALC'H F, ZANTA MA et al.: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA (1995) 92 (16): 7297–72301.
  • THOMAS M, KLIBANOV AM: Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl Acad. Sci. USA (2002) 99(23):14640–14645.
  • AKINC A, THOMAS M, KLIBANOVAM, LANGER R: Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J.Gene Med. (2004) (In Press).
  • SONAWANE ND, SZOKA FC JR, VERKMAN AS: Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. (2003) 278(45):44826–44831.
  • THOMAS M, GE Q, LU JJ, CHEN J, KLIBANOV AM: Cross-linked small polyethylenimines: while still non-toxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm. Res. (2005) (In Press).
  • CHOOSAKOONKRIANG S, LOBO BA, KOE GS, KOE JG, MIDDAUGH CR: Biophysical characterization of PEI/DNA complexes. J. Pharm. Sci. (2003) 92(8):1710–1722.
  • WIGHTMAN L, KIRCHEIS R, ROSSLER Vet al.: Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med. (2001) 3(4):362–372.
  • ZOU SM, ERBACHER P, REMY JS, BEHR JP: Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse./ Gene Med. (2000) 2(2):128–134.
  • TOMPKINS SM, LO CY, TUMPEY TM, EPSTEIN SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Nail. Acad. Sci. USA (2004) 101(23):8682–8686.
  • ••Reports the in vivo inhibition of influenza infection by hydrodynamic transfection of siRNA.
  • THOMAS M, LU JJ, GE Q, ZHENG C, CHEN J, KLIBANOV AM: Full deacylation of polyethylenimine dramatically enhances its gene delivery efficiency and specificity to mouse lung. Proc. Natl Acad. Sci. USA (2005) (In Press).

Websites

  • http://www.cdc.gov/flu CDC influenza information page.
  • http://www.who.int/vaccines/en/ influenza.shtml WHO influenza vaccine page.
  • http://www.wiley.co.uk/genmeci/clinical/ The Journal of Gene Medicine clinical trial website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.